Novartis NOVN 1.69%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology pipeline.
The Swiss pharmaceutical company said Friday that the deal for privately held Excellergy brings in a drug candidate in early-stage trials with potential to complement its existing allergy portfolio.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8